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Abstract
The tumor-stroma ratio (TSR) has been reported as a strong, independent prognostic parameter in colon cancer as well as
in other epithelial cancer types, and may be implemented to routine pathology diagnostics. The TSR is an easy tech-
nique, based on routine hematoxylin and eosin stained histological sections, estimating the amount of stroma present in
the primary tumor. It links tumors with high stromal content to poor prognosis. The analysis time is less than 2 min with
a low inter-observer variation. Scoring of the TSR has been validated in a number of independent international studies.
In this manuscript, we provide a detailed technical description of estimating the TSR in colon cancer, including exam-
ples, pitfalls, and recommendations.
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Introduction
For many years, the choice of optimal treatment of cancer
has mostly been based on clinicopathological characteris-
tics, such as patient age and performance status, tumor
type, malignancy grade, tumor size, and the presence of
regional or distant metastases [1]. Current research in bio-
marker development is focusing more and more on the
tumor microenvironment. Molecular biomarkers based on
tumor characteristics have been developed, but one should
not ignore valuable information provided by the tumor mi-
croenvironment, i.e., the stromal compartment of the tu-
mor. Tumor-stroma plays an important role in cancer initi-
ation and progression, in that the stroma interacts with
nonmalignant cells as well as with malignant cells at dif-
ferent stages of tumorigenesis, ranging from tumor onset to
invasion and metastasis [2].
As shown by our research group, the morphological
evaluation of the tumor microenvironment in convention-
al, routine hematoxylin and eosin (H&E) stained tissue
sections provides valuable information with high prognos-
tic impact. Epithelial malignant tumors from patients with
unfavorable prognosis have been documented to show a
high proportion of stroma (> 50% stroma = stroma-high),
whereas tumors with abundant carcinoma tissue (≤ 50%
stroma = stroma-low) are associated with a better progno-
sis. This phenomenon has led to the development of the
tumor-stroma ratio (TSR) as a prognostic parameter.
Evaluation of this parameter in large patient series has
confirmed its prognostic value for several types of cancers
including colon [3–6], breast [7–9] and esophageal
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00428-018-2408-z) contains supplementary
material, which is available to authorized users.
* W. E. Mesker
W.E.Mesker@lumc.nl
1 Department of Surgery, Leiden University Medical Center,
Albinusdreef 2, 2333 ZA Leiden, Netherlands
2 Department of Clinical Pathology, Vejle Hospital, part of Lillebaelt
Hospital, Vejle, Denmark
3 Department of Pathology, Radboud University Medical Center,
Nijmegen, Netherlands
4 European Society of Pathology, Brussels, Belgium
5 Department of Pathology, Leiden University Medical Center,
Leiden, Netherlands
6 Institute of Regional Health Research, University of Southern
Denmark, Odense, Denmark
7 University Institute of Pathology, Aarhus University Hospital,
Aarhus, Denmark
Virchows Archiv (2018) 473:405–412
https://doi.org/10.1007/s00428-018-2408-z
carcinomas [10]. International groups have validated our
results for colon and breast cancer, and additionally, found
the same prognostic value in other types of epithelial can-
cer, e.g., cervical and lung cancer [11–21]. The TSR scor-
ing technique has been shown to be highly reproducible,
with inter-observer kappa-values ranging from 0.68 to
0.97 (Table 1). Owing its simplicity and reliability, the
TSR may add significant prognostic information to the
currently used TNM classification, and is well-suited
and cost-effective for implementation in routine diagnos-
tics by the pathologist.
In this paper, we describe in detail the technical protocol of
determining the TSR in colon cancer, including examples,
pitfalls, and recommendations.
Method
Slide selection
Slides of the primary tumor are selected from the most invasive
part of the colon adenocarcinoma (i.e., the slides used in routine
pathology to determine the T status). For retrospective studies,
these slides are mostly indicated in the pathology report, and if
not, all available tumor slides are collected and analyzed. In
case of more slides to be analyzed from the most invasive part
of the tumor, the section with the highest percentage of stroma
is scored and decisive for the final estimation of the TSR.
Histopathological scoring
H&E stained tissue sections from the primary tumor of 4 μm
thickness are analyzed by conventional microscopy. Areas
appearing to have the highest amount of stroma are selected
using the × 2.5 or the × 5 lens. Hereafter, an area where both
tumor and stromal tissue are present within this vision-site is
selected using a × 10 objective. Tumor cells are to be present
at all borders of the selected image field (Fig. 1). The amount
of stroma tissue is estimated per 10% increment (10, 20, 30%,
etc.) per image field. For statistical analysis, stromal ratio
groups are divided in stroma-high and stroma-low groups.
Stroma-high is defined as > 50% stromal area, and stroma-
low as ≤ 50% stromal area in the histological section, as de-
termined a priori to have maximum discriminative power [4].
Even if there is only one image field with a stroma-high score,
this image field is decisive.
When scoring the TSR, misinterpretations while estimating
the percentage of stroma can occur due to general issues, as
well as based on specific histological issues. Both are
discussed below.
Table 1 An overview of tumor-
stroma ratio studies reporting an
inter-observer score
Study Number of
patients
Stage Type of cancer Inter-observer
variationa
Mesker et al., 2009 [5] 135 I–II Colon cancer Κ = 0.6–0.7b
(3 observers)
Courrech Staal et al., 2010 [10] 93 I–IV Esophageal cancer Κ = 0.84b
West et al., 2010 [17] 145 I–IV Colorectal cancer Κ = 0.97
De Kruijf et al., 2011 [7] 574 I–III Breast cancer Κ = 0.85b
Moorman et al., 2012 [13] 124 I–III Breast cancer Κ = 0.74b
Wang et al., 2012 [15] 95 I–III Esophageal squamous
cell cancer
Κ = 0.84b
Huijbers et al., 2013 [3] 710 II–III Colon cancer Κ = 0.89b
Dekker et al., 2013 [8] 403 I–II Breast cancer Κ = 0.80b
Downey et al., 2014 [22] 180 I–III Breast cancer (ER+) Κ = 0.70
Park et al., 2014 [14] 250 I–III Colorectal cancer Κ = 0.81b
Liu et al., 2014 [11] 184 I–II Cervical cancer Κ = 0.81b
Zhang et al., 2014 [19] 93 I–IV Nasopharyngeal cancer Κ = 0.85b
Gujam et al., 2014 [21] 361 I–III Breast cancer Κ = 0.83b
Lv et al., 2015 [12] 300 I–IV Hepatocellular cancer Κ = 0.87b
Pongsuvareeyakul et al.,
2015 [23]
131 I–II Cervical Κ = 0.78b
van Pelt et al., 2016 [6] 102 III Colon cancer Κ = 0.73b
Li et al., 2017 [24] 51 II–IV Gallbladder Κ = 0.85b
Roeke et al., 2017 [9] 737 I–III Breast cancer Κ = 0.68b
a Kappa value
b Study in which the method described in this paper was used for scoring the TSR
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General issues
Different oculars
In daily practice, different microscopes are available, with
different lens specifications, leading to different area sizes of
the field of vision. With most used oculars having a diameter
ranging from 18 to 22 mm, the area of the field of vision will
range from 2.54 to 3.80 mm2. However, in exceptional cases,
a larger field of vision will make it able to meet the criterion of
tumor cells needing to be present at all borders, whereas with a
smaller field of vision this might not be possible, or vice versa.
For scoring the TSR, this has not lead to any major differences
in scoring percentages.
Quality of H&E staining
An important factor for determining the TSR is the quality of
the H&E stain. When the stain is too pale or too intense, it is
difficult to distinguish the stromal tissue from the smooth
muscle tissue of the bowel wall. This may happen, when using
too thin or too thick histologic sections, respectively.
If the TSR scoring cannot be carried out optimally due to
the quality of the stain, it is recommended to re-stain the sec-
tion before scoring the TSR.
Only one possibly stroma-high area (stromal
component > 50%)
In case there is only one area/field of vision that might be
categorized as stroma-high, but doubt remains (even after con-
sulting a second observer), we recommend to consider the
total composition of the whole tissue section with the × 2.5
or × 5 objective to classify that particular case. However, if
there is no doubt that the one and only field is stroma-high (or
consensus can be reached), the case is classified as stroma-
high.
Histological issues
It is always preferred to score a field of vision in which no
muscle tissue, necrotic tissue, and/or large blood vessels are
present, but as this might not always be the case, we discuss
Fig. 1 Examples of a stroma-low
(a) and stroma-high (b) colon
carcinoma, which meet the
criteria for the presence of vital
tumor cells on all four sides of the
field of vision (arrows) and are
thus correct for scoring. When
tumor cells are only present at two
(c) or three (d) sides of the field of
vision (mucus is not included in
estimating TSR), these areas are
not suitable for scoring (Images
displaying the microscopic view,
all images × 100 magnification)
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the options below and provide our recommendations, also
regarding other tissue qualities (see Table 2 for a summary).
Mucinous adenocarcinomas
In mucinous cancers, it can be very difficult to estimate the
TSR correctly. The mucus is allowed to be present in the field
of vision, but has to be visually ignored from scoring (Table 2,
Fig. 2a, Supplementary fig. 1). It may also be possible to
determine the TSR in the non-mucinous area of a mucinous
tumor’s deepest penetration of the bowel wall.
Infiltration with inflammatory cells
Heavy inflammation is often encountered within the stromal
component in the tumor microenvironment of colon adeno-
carcinomas, and can be included in the TSR scoring as part of
the stroma. However, lymphoid follicles may represent an
integrated part of the Bnative^ histology of the large bowel,
and thus may not constitute a response to the expanding epi-
thelial tumor within the tumor microenvironment. Thus, we
recommend areas with lymphocytic follicles/aggregates to be
avoided or else visually ignored from scoring (Fig. 2b).
Necrotic tissue
Necrotic tissue or areas with pure neutrophilic inflammation,
which may indicate necrosis, should be left out of the micro-
scopic scoring field. If this is not possible, the necrotic parts
will have to be visually ignored for scoring, as for the mucus
in mucinous tumors (Table 2, Fig. 2c).
Lumen
Almost all tissue sections from colon adenocarcinomas will
contain areas of glandular lumen. These areas should be ig-
nored for scoring (Supplementary fig. 1).
Smooth muscle tissue of the bowel wall
Smooth muscle tissue should be left out of the microscopic
field (Fig. 2d). If this is not possible, the smooth muscle cells
will have to be visually ignored for scoring (Table 2).
In T2-, T3-, and T4-staged adenocarcinomas of the colon,
the tumor cells invade into or through the muscular layer of
the colon. This can cause a mix-up of stromal cells and smooth
muscle cells, which in some cases can be very hard to distin-
guish from one another. To enable an accurate scoring, we
recommend performing an immunohistochemical desmin
stain for these particular cases (Supplementary fig. 2).
Blood vessels
Blood vessels are part of the stroma, and small vessels should
therefore be included in the scoring, being a part of the neo-
angiogenesis in the tumor micro-environment. However,
fields of vision with native, large blood vessel(s) (i.e., thick
smooth muscle wall of more than 3 layers of smooth muscle
Table 2 Summary of the
difficulties occurring during
scoring the tumor-stroma ratio in
colon adenocarcinomas with rec-
ommendations on how to act on
them
Difficulty Recommendation
Mucinous tumor Mucus should be ignored for scoringa
(Abundant) inflammatory cell infiltration Infiltration with inflammatory cells is not an exclusion
criteria and can be included in the scoring.
Necrotic tissue Necrotic tissue should be left out of the microscopic field.
If this is not possible, the necrotic parts will have to be
ignored for scoringa
Smooth muscle tissue Smooth muscle tissue should not be considered for scoring.
In case it is not possible to select a suitable field without
smooth muscle tissue (e.g., in stage II tumors), this tissue
compartment should be ignored for scoring.a A desmin
stain may be of assistance.
Glandular lumen Areas of glandular lumens are ignored for scoringa
Blood vessels Small vessels are included as part of the stroma. Large vessels
with a muscular wall (> 3 layers of smooth muscle cells)
should be avoided or else ignored for scoringa
Tumor budding cells Budding adenocarcinoma cells should be separated from the
surrounding stroma, and may be highlighted by a cytokeratin
stain (AE1/AE3 is recommended) in problematic cases.
Hyalinization Part of the stroma and therefore included for scoring
a To ignore areas for scoring: the microscopic field minus the tissue that has to be visually ignored is set at 100%.
The stroma percentage has to be determined from only the solid (= neoplastic + vital stromal compartment) tissue
parts
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cells) should be replaced by another area for scoring, or, if this
is not possible, the large vessel(s) should be visually ignored
in the scoring (Supplementary Fig. 3a).
Hyalinization
Hyalinization is a change in consistency of the collagenous
matrix in the stromal tumor tissue, which gives the tissue a
Bglassy^ appearance. Being a part of the stroma, it should be
included in the scoring (Supplementary Fig. 3b).
Tumor budding
Tumor budding occurs very often at the invasive front of ad-
enocarcinomas of the colon [25]. Therefore, it is likely that
cell clusters are located in a field of vision chosen for scoring
the TSR. These very small cell clusters can sometimes be hard
to distinguish in H&E stained sections, and they may, falsely,
be ignored as adenocarcinoma cells in the TSR scoring. In
those particular cases, when the (suspected) presence of bud-
ding cells makes it difficult to categorize the TSR estimate as
low or high, it is recommended to perform an immunohisto-
chemical cytokeratin stain (e.g., AE1/AE3) to identify these
malignant epithelial tumor cells (Supplementary Fig. 4).
Discussion
The high interest for the TSR, with sometimes differently used
approaches of the protocol, calls for a standardized and easily
implemented protocol. Although the technique described in
this paper is focused on colon cancer, multiple studies have
proven its robustness and usefulness for other types of solid
epithelial cancers (Table 1). Our method and suggested proto-
col can therefore also be applied to these tumors. This also
includes non-neoadjuvantly treated rectum carcinomas, as
Park et al. showed in their study [14].
Scoring the TSR is a robust method, which only takes little
extra time and costs, and has potential to be implemented in
daily practice. The method is highly reproducible with low
inter-observer variation (see Table 1). Nevertheless, some dif-
ficulties may appear during scoring, as discussed in this paper.
Fig. 2 Examples of infiltration of
a mucinous colon carcinoma (a)
and inflammatory cells (b), which
both meet the criteria for scoring.
For the mucinous colon
carcinoma, the mucus has to be
ignored for scoring. Fields of
vision with necrotic tissue (c) and
smooth muscle tissue (d) do not
meet the scoring criteria and
should not be considered for
scoring (Images displaying the
microscopic view, all images ×
100 magnification)
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In our experience, the biggest challenge is to distinguish be-
tween stromal tissue and smooth muscle fibers, particularly in
stage II colon adenocarcinomas. In challenging cases, we rec-
ommend performing a desmin stain. Being an intermediate
filament, desmin is expressed in both smooth and skeletal
muscle myocytes. Although scoring the TSR is in general an
easy to apply method, in any case of difficulties in scoring, or
doubt by the observer, one may consult a second observer to
his/her own need, according to the usual practice encountering
challenging morphologies.
Also, in case of a stroma percentage at or around the cut-off
point of 50%, consulting a second observer could be of help
when in doubt. In addition, the total composition of the whole
tissue section viewed with a × 5 objective could be considered
to make a final decision.
Scoring of the TSR in colon adenocarcinomas is per-
formed on the tissue slide from the most invasive part of
the tumor, which is the slide used in routine pathology to
determine the T status. This was decided after a study of
colon cancers in which multiple H&E slides from different
areas of the tumor were available for scoring. Although
heterogeneity was seen in the percentage of stroma
throughout the tumor, the highest stroma percentages were
seen in the tumor areas with the deepest penetration in the
bowel wall (higher T-stage) [4].
Most studies have validated our findings of the prognostic
impact of the TSR in various kinds of malignant epithelial
tumors. However, three studies have not been able to demon-
strate validation of the TSR [22, 26, 27]. Discrepancies were
caused by a different interpretation of the TSR scoring meth-
od. Instead of using the highest stroma percentage, these stud-
ies used either the mean percentage in case of heterogeneity
[26], only one area of 9 mm2 at the tumor leading or non-
leading edge [22], or the mean percentage of five image fields
from not only the deepest invasive margin but also adjacent
tumor areas [27]. The latter two studies both used semi-
automated image analysis.
Experimental design
Automated digitized estimation of the TSR allows for a
broader and highly standardized application, and two in-
ternational groups have actually validated our results
using automated image analysis systems [17, 28].
Although this approach might increase reproducibility,
such equipment is rather costly, and not accessible at
all pathological departments yet. In addition, scanning
and analyzing using an automated image analysis system
takes approximately 20 min per slide. In contrast, visual
microscopic scoring of the intra-tumor-stroma ratio can
easily be performed as a routine for conventional mor-
phological diagnosis, and therefore only takes a little
extra time (< 2 min). Moreover, validation studies have
independently reported an inter-observer reproducibility
of substantial to almost perfect between two independent
observers (Table 1). However, in the scope of digitizing
the pathology workflow, automated scoring of the TSR
would suit the diagnostic approach.
Limitations
Assessment of the TSR can be adequately estimated in
patients operated for a primary epithelial malignant neo-
plasm. Neo-adjuvant treatments with chemo- and/or radio-
therapy induce changes to the cellular morphology and
composition of the tumor microenvironment, and result
in stromal formation surrounding the tumor [29–32].
Therefore, patients pre-treated with chemo- and/or radio-
therapy should be excluded for TSR analysis. For these
patients, analyzing pre-treatment biopsies might be a good
alternative, although the TSR cannot be determined at the
most invasive front. As biopsies for colon cancer are rare,
this might not apply for these cases. However, the method
described in this manuscript can be used for several other
epithelial cancer types, for which taking biopsies is more
common practice. This has been nicely demonstrated for
example for esophageal cancer, with the TSR-scores of
the tumor resection correlating with the matching pre-
surgical biopsy TSR-scores in 81% of the cases studied.
In discrepant cases, the biopsy scores were stroma-low,
whereas the surgical removed tumors were scored stro-
ma-high, thereby underestimating the TSR. For stroma-
high cases, however, a 100% correlation was found.
Moreover, TSR biopsy scores showed to be an indepen-
dent prognostic factor for survival [33], which motivates
more investigation into the prognostic and predictive im-
pact of TSR in pre-treatment biopsies from malignant ep-
ithelial tumors.
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